Home/ Stocks/ ALT

Altimmune, Inc. Common Stock

ALT XNAS

$3.08 +0.07 (+2.45%) ▲ 15-min delayed

Open

$3.05

High

$3.10

Low

$3.00

Volume

4.51M

Market Cap

$585.37M

About Altimmune, Inc. Common Stock

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 57 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-22,563,000	$-0.18
FY 2025	$41.0K	$-88,093,000	$-1.00
Q3 2025	$5.0K	$-19,014,000	$-0.21
Q2 2025	$5.0K	$-22,146,000	$-0.27

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for ALT yet. Check out our latest market news or earnings calendar.

Get ALT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Altimmune, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.